(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of 3.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Orchestra Biomed Holdings's revenue in 2024 is $2,760,000.On average, 2 Wall Street analysts forecast OBIO's revenue for 2024 to be $152,411,775, with the lowest OBIO revenue forecast at $125,936,490, and the highest OBIO revenue forecast at $178,887,060. On average, 2 Wall Street analysts forecast OBIO's revenue for 2025 to be $139,353,020, with the lowest OBIO revenue forecast at $99,818,979, and the highest OBIO revenue forecast at $178,887,060.
In 2026, OBIO is forecast to generate $105,006,704 in revenue, with the lowest revenue forecast at $31,126,348 and the highest revenue forecast at $178,887,060.